Longitudinal clinical outcomes across deucravacitinib treatment regimens from Week 16 to Week 32

Published: 22 September 2026| Version 1 | DOI: 10.17632/5bkcv4bm8s.1
Contributors:
Hui Qin, Min Dai, Qian Yu, Yangfeng Ding, Xuemei Yi, Yunlu Gao, Yu Wang, Yifan Hu, Jiajing Lu, Yuling Shi

Description

PASI ≤2 response rates at Weeks 16, 24, and 32 were 100.0%, 90.7% (39/43), and 93.0% (40/43), respectively, in the once-daily maintenance group; 100.0%, 100.0% (30/30), and 46.7% (14/30) in the alternate-day group; and 100.0%, 90.3% (28/31), and 38.7% (12/31) in the on-demand group. In the continued once-daily group with Week 16 PASI >2, PASI ≤2 was achieved by 46.5% (33/71) at Week 24 and 50.7% (36/71) at Week 32. PASI, BSA, and DLQI remained low in the once-daily maintenance group but increased by Week 32 in the alternate-day and on-demand groups

Files

Categories

Psoriasis, Disease Process of Psoriasis

Licence